VC: Cylene leads with $44M round



Cylene leads with $44M round

VENTURE CAPITAL

COMPANY

AMOUNT/ROUND

LEAD INVESTORS

DESCRIPTION

Cylene Pharmaceuticals
San Diego

$44M
Third

HBM BioVentures and Lilly Ventures

The round provides funds for the clinical advancement of small molecule cancer therapies.

4-Antibody
Switzerland

$18.5M
First

Advent Venture Partners

The developer plans to use the money advance new antibodies.

Claros Diagnostics
Woburn, MA

$7.8M
First

Oxford Bioscience Partners

Much of the money earmarked for the development of its handheld diagnostic testing system.

EyeGate Pharma
Waltham, MA

$2M
Second

Nexus Group

EyeGate is exploring the use of iontophoresis technology to deliver therapeutics for ocular indications.

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.